| Catalog No. | SW328046 |
|---|
| Species reactivity | Human |
|---|
| Applications | Research Grade Biosimilar |
|---|
| Isotype | Biosynthetic peptide. |
|---|
| Species | Human |
|---|
| Target | GLP-1 receptor, Glucagon-like peptide 1 receptor, GLP1R, GLP-1-R, GLP-1R, Gastric inhibitory polypeptide receptor, GIPR, GIP-R, Glucose-dependent insulinotropic polypeptide receptor, GCGR, Glucagon receptor, GL-R |
|---|
| Endotoxin level | Please contact with the lab for this information. |
|---|
| Purity | >95% as determined by HPLC. |
|---|
| Purification | Purified by HPLC. |
|---|
| Accession | P43220 & P48546 & P47871 |
|---|
| Form | Liquid |
|---|
| Storage buffer | 0.01M PBS, pH 7.4. |
|---|
| Stability and Storage | Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term. |
|---|
| Alternate Names | LY3437943 |
|---|
| Background | Retatrutide is an investigational triple-hormone receptor agonist developed by Eli Lilly and Company, targeting the receptors for glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1), and glucagon. This unique mechanism aims to address metabolic disorders such as obesity, type 2 diabetes, and non-alcoholic steatohepatitis (NASH). |
|---|
| Note | For research use only. Not suitable for clinical or therapeutic use. |
|---|
